Pulmonology Practice Questions

Q: Which of the following is the common cause of respiratory failure type 2 ?

Chronic bronchitis exacerbation. ***Chronic bronchitis exacerbation*** - **Chronic bronchitis** is a common cause of **Type 2 respiratory failure**, characterized by **hypercapnia** (elevated CO2) due to impaired alveolar ventilation [1]. - An exacerbation worsens **airflow obstruction** and leads to increased work of breathing and CO2 retention [1]. *Acute attack asthma* - While severe asthma can cause respiratory failure, it typically presents initially as **Type 1 (hypoxemic)**, with severe bronchospasm and V/Q mismatch [2]. - **Hypercapnia** in asthma is a sign of **severe, impending respiratory collapse** rather than the primary cause of respiratory failure. *ARDS* - **Acute Respiratory Distress Syndrome (ARDS)** is a classic cause of **Type 1 (hypoxemic) respiratory failure**, characterized by widespread inflammation and fluid accumulation in the lungs [2]. - ARDS primarily involves impaired oxygenation rather than CO2 elimination issues, unless it progresses to severe stages with significant muscle fatigue. *Pneumonia* - **Pneumonia** predominantly causes **Type 1 (hypoxemic) respiratory failure** due to consolidation and V/Q mismatch in affected lung areas, leading to impaired oxygen diffusion [2]. - While severe, widespread pneumonia can eventually lead to ventilatory failure, its initial and primary impact is on oxygenation.

Q: In a patient with COPD, what is the best management option?

Quit smoking. ***Quit smoking*** - **Smoking cessation** is the single most effective intervention for slowing the progression of **COPD** and improving lung function [1]. - It reduces exacerbation rates and improves overall mortality, making it the cornerstone of management [1]. *Bronchodilators* - **Bronchodilators** (e.g., beta-agonists, anticholinergics) are crucial for symptomatic relief by opening airways, but they do not alter the disease progression [1]. - While essential for managing symptoms, they are not the "best" in terms of modifying the disease course. *Low flow oxygen* - **Oxygen therapy** is indicated for patients with **severe hypoxemia** (PaO2 < 55 mmHg or SaO2 < 88%) to improve survival and quality of life [2]. - It is a supportive treatment for advanced disease and does not prevent or slow the progression of COPD itself. *Mucolytics* - **Mucolytics** may be used in some patients with COPD and chronic productive cough to reduce sputum viscosity and improve clearance. - Their benefit is primarily symptomatic, and they do not have a significant impact on disease progression or mortality.

Q: In evaluation of a case of immotile nasal cilia, which of the following investigations should prove useful?

Nitric oxide test. Nitric oxide test - A low nasal nitric oxide (nNO) concentration is a key diagnostic criterion for Primary Ciliary Dyskinesia (PCD), a genetic disorder characterized by immotile or dyskinetic cilia [1]. - Nasal NO is significantly reduced in PCD patients due to impaired ciliary function, making this test highly useful for screening. *Rhinogram* - A rhinogram is a radiographic imaging technique primarily used to visualize the nasal cavity and paranasal sinuses, often to detect structural abnormalities or foreign bodies. - It does not directly assess ciliary function or provide information about ciliary motility. *Sweat sodium levels* - Elevated sweat chloride or sodium levels are the diagnostic hallmark of cystic fibrosis, a genetic condition primarily affecting mucus production. - While cystic fibrosis can cause respiratory symptoms, it does not directly lead to immotile nasal cilia in the same manner as PCD. *Xray nasal and paranasal sinuses* - An X-ray of the nasal and paranasal sinuses can reveal structural issues, such as sinus opacification or polyps, which may accompany ciliary dysfunction. - However, it does not provide direct information about the motility or structural integrity of the cilia themselves.

Q: Which of the following is least likely to be associated with emphysema?

Type I respiratory failure. **Type I respiratory failure** - **Emphysema** primarily causes **Type II respiratory failure** (hypercapnic) due to impaired gas exchange and CO2 retention resulting from alveolar destruction and air trapping [2][4]. - While hypoxemia can occur in severe emphysema, it is the more prominent **hypercapnia** that defines its typical respiratory failure pattern, making pure Type I less likely [3][4]. *Associated with smoking* - **Cigarette smoking** is the leading cause of emphysema, directly linked to the destruction of alveolar walls and loss of elastic recoil [1]. - The inhaled toxins trigger an inflammatory response in the lungs, leading to the release of proteases that break down lung tissue [1][2]. *Barrel shaped chest* - This is a classic sign of advanced emphysema, caused by **chronic air trapping** and subsequent hyperinflation of the lungs [2]. - The diaphragm flattens, and the ribs become more horizontal, increasing the anterior-posterior diameter of the chest. *Cyanosis* - Often seen in patients with severe emphysema (especially in a subgroup referred to as "blue bloaters" for chronic bronchitis overlap) due to **significant hypoxemia** [3]. - Impaired gas exchange leads to insufficient oxygenation of hemoglobin, causing a bluish discoloration of the skin and mucous membranes [3].

Q: Post-tubercular bronchiectasis is most commonly seen with

Tuberculosis. ***Tuberculosis*** - **Tuberculosis (TB)**, particularly childhood TB, is a leading cause of post-infectious bronchiectasis, especially in regions with high TB prevalence [1]. - The inflammatory and destructive processes associated with TB infection in the lungs can lead to irreversible dilation and damage of the bronchi [1]. *Pertussis* - While **pertussis** can cause severe respiratory inflammation and chronic cough, it is a less common cause of widespread, irreversible bronchiectasis compared to tuberculosis [1]. - The damage caused by pertussis is typically more acute and less likely to lead to long-term structural changes like those seen in post-tubercular bronchiectasis. *Cystic fibrosis* - **Cystic fibrosis** is a genetic disorder that causes thick, sticky mucus to build up in the lungs, leading to chronic infections and bronchiectasis [1]. - However, post-tubercular bronchiectasis refers specifically to bronchiectasis developing *after* a tuberculosis infection, not as a primary genetic condition. *Kartagener syndrome* - **Kartagener syndrome** is a genetic disorder characterized by defects in ciliary function, leading to impaired mucociliary clearance and recurrent respiratory infections, which can result in bronchiectasis [1]. - Similar to cystic fibrosis, this is a primary genetic cause of bronchiectasis, distinct from bronchiectasis occurring as a sequela of tuberculosis.

Q: What is the best immediate management strategy for a patient experiencing respiratory alkalosis due to anxiety-induced hyperventilation?

Rebreathing in paper bag. ***Rebreathing in paper bag*** - This helps to **increase the inspired CO2 concentration**, thereby correcting the hypocapnia (low CO2) caused by hyperventilation. - It's a simple, non-invasive method to raise arterial PCO2 and normalize blood pH in acute respiratory alkalosis. *IPPV* - **Intermittent positive pressure ventilation (IPPV)** would further reduce CO2 by assisting ventilation and is typically used for respiratory *acidosis* or failure [1]. - This intervention would worsen the patient's respiratory alkalosis rather than alleviating it. *Normal saline* - **Normal saline** administration is primarily used for volume expansion or to correct electrolyte imbalances; it does not directly address respiratory alkalosis. - It would not correct the underlying issue of excessive CO2 exhalation. *Acetazolamide* - **Acetazolamide** is a carbonic anhydrase inhibitor that reduces bicarbonate reabsorption and is used to treat metabolic alkalosis or as a diuretic. - It would not be an immediate or appropriate solution for acute respiratory alkalosis and might even worsen the acid-base balance if used improperly.

Q: The physiological marker of the last stage of acute asthma is

Increased carbon dioxide levels (Hypercapnia). ***Increased carbon dioxide levels (Hypercapnia)*** - In severe, acute asthma, **air trapping** and **muscle fatigue** lead to inadequate ventilation and impaired gas exchange [1]. - This results in a buildup of carbon dioxide in the blood, indicating impending **respiratory failure** and a critical stage of the asthma exacerbation [3]. *Hypocapnia* - **Hypocapnia**, or low blood CO2, is common in the **early stages** of an asthma attack due to **tachypnea** (rapid breathing) in an effort to compensate [1]. - As the condition worsens, the ability to ventilate adequately diminishes, leading to CO2 retention [3]. *Hyperoxia* - **Hyperoxia** means abnormally high levels of oxygen in the blood, which is generally not a physiological marker of acute asthma. - Patients with acute asthma typically experience **hypoxemia** (low oxygen levels) due to ventilation-perfusion mismatch [1]. *Alkalosis* - **Respiratory alkalosis** (high pH due to low CO2) can occur in the early stages as patients **hyperventilate**. - However, in the late stages, as CO2 builds up (**hypercapnia**), the patient shifts towards **respiratory acidosis** (low pH), which is a sign of severe compromise [2], [3].

Q: Which of the following is not a clinical feature of Bronchiectasis?

Night sweats. ***Night sweats*** - While **night sweats** can be present in chronic infections, they are not considered a primary or defining clinical feature directly associated with the pathology of bronchiectasis itself. - They are more commonly linked with systemic conditions like **tuberculosis** or malignancy, which would require alternative diagnostic pathways. *Hemoptysis* - **Hemoptysis** (coughing up blood) is a common and often alarming symptom of bronchiectasis due to the inflammation and damage to the bronchial walls and underlying vasculature [1]. - Blood vessels in damaged airways are prone to rupture, leading to bleeding, which can range from blood-streaked sputum to massive hemorrhage [1]. *Chest pain* - **Chest pain** can occur in bronchiectasis, often related to the chronic cough, pleural inflammation, or musculoskeletal strain from persistent coughing. - It can also be a symptom if there's an associated infection or inflammation extending to the pleura. *Productive cough* - A **chronic productive cough** with significant amounts of purulent sputum is the hallmark symptom of bronchiectasis [1]. - This is due to the impaired mucociliary clearance and chronic infection within the dilated, damaged airways .

Q: Which of the following is not an obstructive lung disease?

Interstitial fibrosis. ***Interstitial fibrosis*** - **Interstitial fibrosis** is a **restrictive lung disease**, characterized by **reduced lung elasticity** and lung volumes, rather than airway obstruction [1]. - In this condition, the **lung tissue becomes scarred and stiff**, making it difficult to expand fully during inspiration [1]. *Emphysema* - **Emphysema** is a classic **obstructive lung disease** caused by the destruction of the **alveolar walls**, leading to enlarged air spaces and loss of elastic recoil [3]. - This destruction results in **airflow limitation**, particularly during exhalation, as airways collapse prematurely. *Asthma* - **Asthma** is an **obstructive lung disease** characterized by **reversible airway inflammation**, bronchoconstriction, and increased mucus production [2]. - These factors lead to **episodic airflow obstruction**, making it difficult to breathe, especially during exacerbations [2]. *Bronchitis* - **Bronchitis**, particularly **chronic bronchitis**, is an **obstructive lung disease** defined by chronic inflammation of the bronchi. - This inflammation causes **mucus hypersecretion** and narrowing of the airways, leading to persistent cough and airflow limitation.

Question 1

Which of the following is the common cause of respiratory failure type 2 ?

Accepted Answer

Chronic bronchitis exacerbation

Answer

Acute attack asthma

Answer

ARDS

Answer

Pneumonia

Question 2

In a patient with COPD, what is the best management option?

Accepted Answer

Quit smoking

Answer

Bronchodilators

Answer

Low flow oxygen

Answer

Mucolytics

Question 3

In evaluation of a case of immotile nasal cilia, which of the following investigations should prove useful?

Accepted Answer

Nitric oxide test

Answer

Rhinogram

Answer

Sweat sodium levels

Answer

Xray nasal and paranasal sinuses

Question 4

Which of the following is least likely to be associated with emphysema?

Accepted Answer

Type I respiratory failure

Answer

Associated with smoking

Answer

Barrel shaped chest

Answer

Cyanosis

Question 5

Post-tubercular bronchiectasis is most commonly seen with

Accepted Answer

Tuberculosis

Answer

Pertussis

Answer

Cystic fibrosis

Answer

Kartagener syndrome

Question 6

What is the best immediate management strategy for a patient experiencing respiratory alkalosis due to anxiety-induced hyperventilation?

Accepted Answer

Rebreathing in paper bag

Answer

IPPV

Answer

Normal saline

Answer

Acetazolamide

Question 7

The physiological marker of the last stage of acute asthma is

Accepted Answer

Increased carbon dioxide levels (Hypercapnia)

Answer

Hypocapnia

Answer

Hyperoxia

Answer

Alkalosis

Question 8

Which of the following is not a clinical feature of Bronchiectasis?

Accepted Answer

Night sweats

Answer

Hemoptysis

Answer

Chest pain

Answer

Productive cough

Question 9

Which of the following statements is true regarding the diagnostic criteria for Chronic Obstructive Pulmonary Disease (COPD)?

Accepted Answer

A post-bronchodilator FEV1/FVC ratio below the threshold indicates airflow limitation.

Answer

A post-bronchodilator FEV1/FVC ratio above the threshold indicates normal lung function.

Answer

Residual Volume (RV) is normal.

Answer

Total Lung Capacity (TLC) is decreased.

Question 10

Which of the following is not an obstructive lung disease?

Accepted Answer

Interstitial fibrosis

Answer

Emphysema

Answer

Asthma

Answer

Bronchitis

Pulmonology — MCQs

Pulmonology — MCQs

On this page

Practice by Chapter

Want unlimited practice?